"The US Food and Drug Administration (FDA) today approved asfotase alfa (Strensiq, Alexion Pharmaceuticals) as the first-ever therapy for patients who develop hypophosphatasia, a rare metabolic bone disorder, in childhood.
(Generic versions may still be available.)
Evidence indicates that the symptoms of Parkinson's disease are related to depletion of striatal dopamine. Since dopamine apparently does not cross the blood-brain barrier, its administration is ineffective in the treatment of Parkinson's disease. However, levodopa, the levorotatory isomer of dihydroxy-phenylalanine (dopa) which is the metabolic precursor of dopamine, does cross the blood-brain barrier. Presumably it is converted into dopamine in the basal ganglia. This is generally thought to be the mechanism whereby oral levodopa acts in relieving the symptoms of Parkinson's disease.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Dopar Information
- Dopar Drug Interactions Center: levodopa oral
- Dopar Side Effects Center
- Dopar FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.